Research GISTs – GIST Cancer UK
Researchers plan to investigate why some GISTs with mutations in different exons react differently to the common drugs.
Understanding these differential drug responses could enable clinicians to tailor therapy more precisely, potentially improving treatment efficacy and reducing the likelihood of relapse.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Disproportionality analysis of adverse events associated with tyrosine kinase inhibitors in gastrointestinal stromal tumors in the FDA adverse event reporting system
- Review of Genomic Testing and SDH Deficiency in Gastrointestinal Stromal Tumors: Getting to the GIST
- Molecular Tailored Therapeutic Options for Advanced Gastrointestinal Stromal Tumors (GISTs): Current Practice and Future Perspectives
- Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach
- UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST)